Abilene Scientist Receives Grant to Research Novel Brain Tumor Treatment

Saha to Investigate Use of Viruses to Attack, Weaken Deadly Glioblastoma Cells

Dipongkor Saha, D.V.M., Ph.D.

An estimated 700,000 people in the U.S. are living with a brain tumor and nearly 80,000 new cases are diagnosed each year. Glioblastoma (GBM), an aggressive cancer most often found in the brain, is responsible for more than 75% of these tumors. Currently there are no effective treatments for GBM, which is almost always fatal, and most patients die 12-18 months after initial diagnosis.

In an effort to improve the prognosis for GBM patients, the U.S. Department of Defense recently awarded a $550,491 grant to Dipongkor Saha, D.V.M., Ph.D., a cancer immunologist and assistant professor of immunotherapeutics and biotechnology at the Texas Tech University Health Sciences Center (TTUHSC) Jerry H. Hodge School of Pharmacy in Abilene.

“Our goal is to develop a novel and safe treatment strategy that should provide treatment relief to a significant number of individuals suffering from this devastating disease,” Saha said.

Saha’s current research is primarily focused on inciting anti-tumor immunity, which is when the body recognizes and begins an immune response to certain antigens expressed by cancer, known as tumor associated antigens (TAAs). He is investigating the use of oncolytic virus therapy, which uses certain viruses to attack and compromise cancer cells while leaving the adjacent healthy cells to function normally. The process can kill cancer cells or weaken them so that other treatments like radiation and chemotherapy may be more effective.

In the studies proposed by his new grant, Saha said he not only will investigate how to effectively induce immunity against tumor cells, but also seek ways to divert the body’s immune system specifically toward TAAs.

“Importantly, TAAs are exclusively present in cancer cells, but absent or present at an insignificant level in healthy cells,” Saha explained. “Therefore, the TAA-targeted treatments will only kill cancer cells while sparing healthy cells, thus conferring safety to treated individuals.”

Saha’s grant funding began Sept. 1 and is scheduled to run through August 2023.

Related Stories

TTUHSC’s Graduate School of Biomedical Sciences Hosts Student Research Week

The Texas Tech University Health Sciences Center (TTUHSC) Graduate School of Biomedical Sciences hosted its 34th Annual Student Research Week March 8-11.

TTUHSC Researcher Receives NIH Grant to Study Vulnerabilities in Specific Cancer Types

The National Cancer Institute awarded a five-year, $1.9 million grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at TTUHSC.

The Hype Around Artificial Intelligence

Richard Greenhill, DHA, FISQua, FACHE, discusses the hype and reality surrounding AI in healthcare.

Recent Stories

Education

Developing Troubleshooting Skills in Molecular Pathology Students

Ericka Hendrix, PhD, MB(ASCP)cm, spoke about the training and education involved for diagnostic molecular scientists and how the pandemic has affected the role.

Education

Celebrating Collaboration — TTUHSC and City of Abilene Unveil New Julia Jones Matthews School of Population and Public Health

TTUHSC and members of the Abilene community today (June 29) celebrated the official unveiling the new Julia Jones Matthews School of Population and Public Health.

Education

A Sixth School for a Brighter Future

On June 29, the opening celebration event for the Julia Jones Matthews School of Population and Public Health will recognize many years of hard work and look ahead to the start of a new and exciting journey.